Sucampo Announces Webcast of Its Presentation at the Jefferies 2015 Healthcare Conference
May 27 2015 - 6:45AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will webcast its
corporate presentation at the Jefferies 2015 Healthcare Conference
taking place June 3, 2015 at 4:00 PM ET.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
The presentation will be webcast live and may be accessed from
the Event & Presentations page of Sucampo's website at
http://www.sucampo.com/investors/events-presentations/.
Presentation slides will be available via the webcast links. A
replay of the webcast will also be available on the Company's
website for several days after the live event. To ensure a timely
connection, it is recommended that users register at least 15
minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., is a global biopharmaceutical
company that is built on the ongoing pursuit of scientific
innovation to improve the lives of patients. Sucampo has a marketed
product – AMITIZA – and a pipeline including lifecycle management
and clinical development programs. Sucampo is headquartered in
Bethesda, Maryland, and has operations in Japan, Switzerland and
the U.K. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals).
Twitter LinkedIn
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; the ability of Sucampo to continue to
develop the market for AMITIZA; the ability of Sucampo to develop,
commercialize or license existing pipeline products or compounds or
license or acquire non-prostone products or drug candidates;
Sucampo's ability to accurately predict future market conditions;
dependence on the effectiveness of Sucampo's patents and other
protections for innovative products; the risk of new and changing
regulation and health policies in the U.S. and internationally; the
effects of competitive products on Sucampo's products; and the
exposure to litigation and/or regulatory actions.
No forward-looking statement can be guaranteed and actual
results may differ materially from those projected. Sucampo
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk
factors and cautionary statements in Sucampo's most recent Form
10-K as filed with the Securities and Exchange Commission on March
9, 2015 as well as its filings with the Securities and Exchange
Commission on Forms 8-K and 10-Q since the filing of the Form 10-K,
all of which Sucampo incorporates by reference.
CONTACT: Silvia Taylor
Senior Vice President,
Investor Relations and Corporate Communications
240-223-3718
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024